Cargando…
Purinergic Signaling of ATP in COVID-19 Associated Guillain-Barré Syndrome
Declared as a global public health emergency, coronavirus disease 2019 (COVID-19) is presented as a disease of the respiratory tract, although severe cases can affect the entire organism. Several studies have shown neurological symptoms, ranging from dizziness and loss of consciousness to cerebrovas...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813171/ https://www.ncbi.nlm.nih.gov/pubmed/33462776 http://dx.doi.org/10.1007/s11481-020-09980-1 |
_version_ | 1783637806532263936 |
---|---|
author | Simões, Júlia Leão Batista Bagatini, Margarete Dulce |
author_facet | Simões, Júlia Leão Batista Bagatini, Margarete Dulce |
author_sort | Simões, Júlia Leão Batista |
collection | PubMed |
description | Declared as a global public health emergency, coronavirus disease 2019 (COVID-19) is presented as a disease of the respiratory tract, although severe cases can affect the entire organism. Several studies have shown neurological symptoms, ranging from dizziness and loss of consciousness to cerebrovascular and neurodegenerative diseases. In this context, Guillain-Barré syndrome, an immune-mediated inflammatory neuropathy, has been closely associated with critical cases of infection with “severe acute respiratory syndrome of coronavirus 2” (SARS-CoV-2), the etiological agent of COVID-19. Its pathophysiology is related to a generalized inflammation that affects the nervous system, but neurotropism was also revealed by the new coronavirus, which may increase the risk of neurological sequel, as well as the mortality of the disease. Thus, considering the comorbidities that SARS-CoV-2 infection can promote, the modulation of purinergic signaling can be applied as a potential therapy. In this perspective, given the role of adenosine triphosphate (ATP) in neural intercommunication, the P2X7 receptor (P2X7R) acts on microglia cells and its inhibition may be able to reduce the inflammatory condition of neurodegenerative diseases. Finally, alternative measures to circumvent the reality of the COVID-19 pandemic need to be considered, given the severity of critical cases and the viral involvement of multiple organs. GRAPHICAL ABSTRACT: [Image: see text] |
format | Online Article Text |
id | pubmed-7813171 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-78131712021-01-18 Purinergic Signaling of ATP in COVID-19 Associated Guillain-Barré Syndrome Simões, Júlia Leão Batista Bagatini, Margarete Dulce J Neuroimmune Pharmacol Invited Review Declared as a global public health emergency, coronavirus disease 2019 (COVID-19) is presented as a disease of the respiratory tract, although severe cases can affect the entire organism. Several studies have shown neurological symptoms, ranging from dizziness and loss of consciousness to cerebrovascular and neurodegenerative diseases. In this context, Guillain-Barré syndrome, an immune-mediated inflammatory neuropathy, has been closely associated with critical cases of infection with “severe acute respiratory syndrome of coronavirus 2” (SARS-CoV-2), the etiological agent of COVID-19. Its pathophysiology is related to a generalized inflammation that affects the nervous system, but neurotropism was also revealed by the new coronavirus, which may increase the risk of neurological sequel, as well as the mortality of the disease. Thus, considering the comorbidities that SARS-CoV-2 infection can promote, the modulation of purinergic signaling can be applied as a potential therapy. In this perspective, given the role of adenosine triphosphate (ATP) in neural intercommunication, the P2X7 receptor (P2X7R) acts on microglia cells and its inhibition may be able to reduce the inflammatory condition of neurodegenerative diseases. Finally, alternative measures to circumvent the reality of the COVID-19 pandemic need to be considered, given the severity of critical cases and the viral involvement of multiple organs. GRAPHICAL ABSTRACT: [Image: see text] Springer US 2021-01-18 2021 /pmc/articles/PMC7813171/ /pubmed/33462776 http://dx.doi.org/10.1007/s11481-020-09980-1 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Invited Review Simões, Júlia Leão Batista Bagatini, Margarete Dulce Purinergic Signaling of ATP in COVID-19 Associated Guillain-Barré Syndrome |
title | Purinergic Signaling of ATP in COVID-19 Associated Guillain-Barré Syndrome |
title_full | Purinergic Signaling of ATP in COVID-19 Associated Guillain-Barré Syndrome |
title_fullStr | Purinergic Signaling of ATP in COVID-19 Associated Guillain-Barré Syndrome |
title_full_unstemmed | Purinergic Signaling of ATP in COVID-19 Associated Guillain-Barré Syndrome |
title_short | Purinergic Signaling of ATP in COVID-19 Associated Guillain-Barré Syndrome |
title_sort | purinergic signaling of atp in covid-19 associated guillain-barré syndrome |
topic | Invited Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813171/ https://www.ncbi.nlm.nih.gov/pubmed/33462776 http://dx.doi.org/10.1007/s11481-020-09980-1 |
work_keys_str_mv | AT simoesjulialeaobatista purinergicsignalingofatpincovid19associatedguillainbarresyndrome AT bagatinimargaretedulce purinergicsignalingofatpincovid19associatedguillainbarresyndrome |